出版应用/物种/样本/稀释 | 参考文献 |
---|
| Mahoney K, Shukla S, Patsoukis N, Chaudhri A, Browne E, Arazi A, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019;68:421-432 pubmed 出版商
|
| Wang F, Ye W, He Y, Zhong H, Zhu Y, Han J, et al. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. Int J Mol Sci. 2023;24: pubmed 出版商
|
| Parkinson J, Hard R, Wang W. The RESP AI model accelerates the identification of tight-binding antibodies. Nat Commun. 2023;14:454 pubmed 出版商
|
| Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10: pubmed 出版商
|
| He B, Li B, Chen X, Zhang Q, Lu C, Yang S, et al. PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors. Front Microbiol. 2022;13:928774 pubmed 出版商
|
| Jiao L, Dong Q, Zhai W, Zhao W, Shi P, Wu Y, et al. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy. Pharmacol Res. 2022;182:106343 pubmed 出版商
|
| Banta K, Xu X, Chitre A, Au Yeung A, Takahashi C, O Gorman W, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity. 2022;55:512-526.e9 pubmed 出版商
|
| Cui X, Jia H, Xin H, Zhang L, Chen S, Xia S, et al. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities. Front Immunol. 2021;12:778978 pubmed 出版商
|
| Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536 pubmed 出版商
|
| Jeong S, Park E, Kim H, Sung E, Kim H, Jeon J, et al. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer. 2021;9: pubmed 出版商
|
| Sasikumar P, Sudarshan N, Adurthi S, Ramachandra R, Samiulla D, Lakshminarasimhan A, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol. 2021;4:699 pubmed 出版商
|
| Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, et al. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Front Immunol. 2021;12:654463 pubmed 出版商
|
| Li M, Zhao R, Chen J, Tian W, Xia C, Liu X, et al. Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo. Sci Rep. 2021;11:5774 pubmed 出版商
|
| Xing Y, Liu J, Sun S, Ming T, Wang Y, Luo J, et al. New electrochemical method for programmed death-ligand 1 detection based on a paper-based microfluidic aptasensor. Bioelectrochemistry. 2021;140:107789 pubmed 出版商
|
| Wang F, Ye W, Wang S, He Y, Zhong H, Wang Y, et al. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia. 2021;23:281-293 pubmed 出版商
|
| Schofield D, Percival Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, et al. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. MAbs. 2021;13:1857100 pubmed 出版商
|
| Gu T, Zhao S, Jin G, Song M, Zhi Y, Zhao R, et al. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model. Front Immunol. 2020;11:621441 pubmed 出版商
|
| Wu X, Li F, Li Y, Yu Y, Liang C, Zhang B, et al. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. Med Sci Monit. 2020;26:e925583 pubmed 出版商
|
| Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol. 2020;219: pubmed 出版商
|
| Zhao Y, Lee C, Lin C, Gassen R, Xu X, Huang Z, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity. 2019;51:1059-1073.e9 pubmed 出版商
|
| Hassounah N, Malladi V, Huang Y, Freeman S, Beauchamp E, Koyama S, et al. Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunol Immunother. 2019;68:407-420 pubmed 出版商
|
| Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J, et al. Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Front Immunol. 2018;9:1614 pubmed 出版商
|
| Ansari N, Ghazvini K, Ramezani M, Shahdordizadeh M, Yazdian Robati R, Abnous K, et al. Selection of DNA aptamers against Mycobacterium tuberculosis Ag85A, and its application in a graphene oxide-based fluorometric assay. Mikrochim Acta. 2017;185:21 pubmed 出版商
|
| Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, et al. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res. 2018;6:178-188 pubmed 出版商
|
| Haworth K, Arnold M, Pierson C, Choi K, Yeager N, Ratner N, et al. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget. 2017;8:82037-82048 pubmed 出版商
|
| Shahdordizadeh M, Taghdisi S, Sankian M, Ramezani M, Abnous K. Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitro. Int Immunopharmacol. 2017;53:96-104 pubmed 出版商
|
| Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, et al. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget. 2017;8:41932-41946 pubmed 出版商
|
| Li Q, Quan L, Lyu J, He Z, Wang X, Meng J, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget. 2016;7:64967-64976 pubmed 出版商
|